Phaseline

Companies › Aptamer Sciences

Aptamer Sciences: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AST-201
GPC3-targeting aptamer
GPC3Phase 1NeoplasmsDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06687941AST-201Phase 1NeoplasmsOncologyDec 2027

Targets

GPC3 (1)

Companies with the same targets

AstraZeneca Keymed Biosciences Co.Ltd Newish Technology (Beijing) Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Zymeworks BC RayzeBio SOTIO Biotech Bayer BeOne Medicines

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.